ImmunoCellular allows IND for ICT-140 ImmunoCellular Therapeutics announced that the FDA has allowed the investigational new drug, or IND, application for ICT-140, paving the way for conducting a clinical trial. ICT-140 is a dendritic cell vaccine targeting seven antigens that are over-expressed in ovarian cancer, as well as cancer stem cells. ImmunoCellular filed the IND application with the FDA in the Q4 of FY12, as planned.
News For IMUC From The Last 14 Days
Check below for free stories on IMUC the last two weeks.